Form 4 · Filed Jul 6, 2026, 08:31 PM UTC
KROS/Keros Therapeutics, Inc.
Prener Anne — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
2 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | A | other | 13,786 | $0 | — | 13,786 |
| Jul 1, 2026 | A | other | 14,870 | — | — | 14,870 |
Source: SEC EDGAR raw filing ↗ · Accession 0001797917-26-000007